Background: Patients with coronavirus disease 2019 (COVID-19) who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19. Methods: A systematic literature search involving peer-reviewed publications, preprints and conference proceedings up to July 16, 2020, was performed. The primary end-point was the case fatality rate (CFR), defined as the rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI). Results: Fifty-two studies, involving a total of 18,650 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 4243 deaths were recorded in this population. The probability of death was 25.6% (95% CI: 22.0%–29.5%; I2 = 48.9%) in this patient population. Conclusions: Patients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer and to optimally manage those who do contract the infection.

Mortality in patients with cancer and coronavirus disease 2019 : A systematic review and pooled analysis of 52 studies / K.S. Saini, M. Tagliamento, M. Lambertini, R. McNally, M. Romano, M. Leone, G. Curigliano, E. de Azambuja. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 139(2020), pp. 43-50. [10.1016/j.ejca.2020.08.011]

Mortality in patients with cancer and coronavirus disease 2019 : A systematic review and pooled analysis of 52 studies

G. Curigliano
Conceptualization
;
2020

Abstract

Background: Patients with coronavirus disease 2019 (COVID-19) who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19. Methods: A systematic literature search involving peer-reviewed publications, preprints and conference proceedings up to July 16, 2020, was performed. The primary end-point was the case fatality rate (CFR), defined as the rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI). Results: Fifty-two studies, involving a total of 18,650 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 4243 deaths were recorded in this population. The probability of death was 25.6% (95% CI: 22.0%–29.5%; I2 = 48.9%) in this patient population. Conclusions: Patients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer and to optimally manage those who do contract the infection.
Cancer; CFR; COVID-19; Death rate; Malignancy; Mortality; Pandemic; SARS-CoV-2; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Neoplasms; Pandemics; Pneumonia, Viral; Prognosis; SARS-CoV-2; Survival Rate
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Saini and EJC and Curigliano.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 831.34 kB
Formato Adobe PDF
831.34 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/824861
Citazioni
  • ???jsp.display-item.citation.pmc??? 126
  • Scopus 199
  • ???jsp.display-item.citation.isi??? 189
social impact